Stock Markets June 22, 2026 08:38 AM

Deal Activity, Biotech Moves and Bitcoin Miners Lift U.S. Futures in Premarket

Apogee surges after AbbVie acquisition announcement; Bitcoin-linked miner announces buyback; energy and pharma names also advance

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
APGE ABBV FUFU NVCT

U.S. stock futures ticked higher in premarket trading as investors absorbed a major biotech acquisition and several company-specific developments across biotechnology, cryptocurrency-related mining, pharmaceuticals and energy. Apogee Therapeutics jumped after AbbVie agreed to acquire the company for $10.9 billion, while BitFuFu unveiled a $5 million share repurchase plan. Other movers included Nuvectis, Palvella and Chevron.

Deal Activity, Biotech Moves and Bitcoin Miners Lift U.S. Futures in Premarket
APGE ABBV FUFU NVCT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • A major acquisition in biotechnology drove a large pop in Apogee Therapeutics shares and modest gains for AbbVie, affecting the immunology sector.
  • Bitcoin-linked equity BitFuFu rose after announcing a $5 million buyback program, highlighting investor interest in miners and crypto-related corporate actions.
  • Energy and infrastructure markets responded to Chevron’s 20-year power purchase agreement with Microsoft for a proposed West Texas data center, an arrangement expected to deliver about 2.67 gigawatts beginning in 2028.

U.S. equity futures inched upward on Monday as market participants digested an active string of corporate announcements spanning biotechnology, Bitcoin-linked miners and energy contract news.

At 08:34 ET (12:34 GMT), S&P 500 futures were up 0.1%, Nasdaq 100 futures rose 0.4%, and Dow futures advanced 0.3%.


Below are the most notable premarket stock moves:

  • Apogee Therapeutics experienced a dramatic surge, with shares jumping 47% after AbbVie agreed to acquire the biotechnology company for $10.9 billion. The transaction represents AbbVie’s largest purchase in more than five years and is positioned to expand the drugmaker’s next-generation immunology pipeline.

  • AbbVie shares rose 1.5% following the announcement of the takeover of Apogee Therapeutics as the company looks to broaden its immunology treatment portfolio and add new growth drivers.

  • BitFuFu advanced 8.2% after the Bitcoin miner disclosed a share repurchase program authorizing the buyback of up to $5 million of its Class A ordinary shares over a two-year period.

  • Nuvectis Pharma climbed 5.7% after entering a licensing agreement with Haisco Pharmaceutical Group covering exclusive ex-China rights to two clinical-stage drug candidates. The deal brings a Complement Factor B inhibitor and a BRAF inhibitor into Nuvectis’ pipeline.

  • Palvella Therapeutics increased 5% after the U.S. Food and Drug Administration granted a rolling review for its New Drug Application for QTORIN rapamycin, a drug in development for microcystic lymphatic malformations.

  • Chevron gained 1.3% following the announcement of a 20-year power purchase agreement with Microsoft. Under the pact, Chevron will supply natural gas-fired electricity to a proposed data center campus in West Texas. The project is expected to provide roughly 2.67 gigawatts of capacity and to begin supplying power in 2028.


These premarket moves reflect investor focus on corporate dealmaking and company-level strategic actions across multiple sectors. Biotech names attracted particular attention after the AbbVie-Apogee transaction brought a substantial premium to Apogee’s shares and modest gains for AbbVie. Cryptocurrency-linked equities also moved higher after a buyback program was announced by a miner, while energy and infrastructure-related news received attention following Chevron’s long-term agreement tied to a proposed data center in West Texas.

The spread of activity illustrates how single-company developments - from licensing deals and regulatory reviews to acquisitions and share repurchases - can have outsized effects on premarket sentiment and trading directions.

Risks

  • Palvella Therapeutics faces regulatory uncertainty as its New Drug Application for QTORIN rapamycin is under rolling review by the U.S. Food and Drug Administration - this affects the biotech and medical therapeutics sector.
  • Nuvectis Pharma’s licensing deal grants exclusive ex-China rights, which limits geographic commercial rights for the two clinical-stage candidates and affects the company’s potential market reach in pharmaceuticals.
  • Chevron’s agreement to supply a proposed data center in West Texas is tied to a project described as proposed and to a multi-year timeline with power expected to begin in 2028, indicating project development and timeline uncertainty in energy and infrastructure.

More from Stock Markets

Goldman Says Rapid EV Uptake Could Cut Oil Demand by as Much as 0.32 mb/d by 2027 Jun 22, 2026 Tesla stuck between $380 and $420 as momentum and trend indicators clash Jun 22, 2026 CleanSpark Shares Rally on Bitcoin Strength and Potential AI Lease at Sandersville Jun 22, 2026 MDA Space Shares Jump After Agreement to Buy Blue Canyon Technologies for US$620 Million Jun 22, 2026 AeroVironment Shares Drop After Accounting Restatement Enlarges Space Unit Losses Jun 22, 2026